ImmunityBio's Major Investor Bolsters Stake Amid Legal and Regulatory Challenges

Patrick Soon-Shiong converts $25M debt to shares as ImmunityBio secures $75M funding, advances cancer trials, and faces FDA warning letters and a lawsuit.

In a significant show of confidence, ImmunityBio's largest shareholder is increasing his stake as the biotechnology firm navigates a complex landscape of regulatory scrutiny and legal action. Patrick Soon-Shiong, through his investment vehicle Nant Capital, has converted substantial debt into company shares, a move that coincides with both financial reinforcement for the company and a contentious period involving the U.S. Food and Drug Administration (FDA).

Debt Conversion and Financial Reinforcement

The transaction, executed in late March 2026, saw Nant Capital convert a $25 million convertible note into approximately 4.6 million shares of common stock. The conversion price was set at $5.427 per share, notably below the trading price at that time. This strategic conversion elevates Soon-Shiong's direct and indirect control to over 280 million shares in the company.

This capital move is part of a broader financing strategy. Separately, ImmunityBio secured $75 million in non-dilutive capital from Oberland Capital. The combined financial injections are intended to strengthen the company's balance sheet, providing extended runway for the global commercialization of its product portfolio.

Operational Progress Provides Counterweight

Despite surrounding challenges, ImmunityBio's clinical development pipeline continues to advance. The company's QUILT-2.005 Phase 3 trial is now fully enrolled and possesses sufficient statistical power. Furthermore, a significant clinical endorsement was achieved: the combination therapy involving the drug Anktiva has been included in the 2026 National Comprehensive Cancer Network (NCCN) guidelines for the treatment of specific bladder cancer types.

Looking ahead through 2026, the company anticipates key milestones. Plans are in place to submit a supplemental Biologics License Application (sBLA), with pivotal clinical data expected in the latter half of the year. These operational developments form a core part of the investment thesis for supporters.

Mounting Legal and Regulatory Scrutiny

The shareholder's vote of confidence arrives during a turbulent phase for ImmunityBio. The company's stock had previously declined by approximately 24%, a drop triggered by an FDA warning letter concerning misleading promotional claims for Anktiva. The regulatory situation is compounded by a filed securities class action lawsuit, which alleges the company's management misrepresented Anktiva's capabilities by falsely promoting it as a "cancer vaccine."

FDA documentation reveals a particularly serious detail: a subsidiary of ImmunityBio had received similar promotional violation letters in September 2025 and January 2026. According to the agency, the company continued the disputed marketing practices in television commercials and podcasts despite these prior warnings.

Market Reaction and Analyst Perspective

In recent trading, ImmunityBio's shares have shown signs of recovery, climbing roughly seven percent toward the $7.92 level. Analysts at BTIG have weighed in, characterizing the advertising issues as resolvable and maintaining that the fundamental outlook for the company remains intact.

The investment narrative for ImmunityBio now exists at the intersection of two opposing forces: the forward momentum of its clinical programs and the ongoing legal and regulatory repercussions from its marketing practices. The actions of its largest investor suggest a belief that the former will ultimately outweigh the latter.